Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorChinese PLA General Hospital
About this trial
The purpose of this study is to systematically evaluate the efficacy and safety of bacteriophage cocktail therapy in patients with ventilator-associated pneumonia caused by Gram-negative bacterial infections.
Eligibility criteria
Qualifiers
Diagnosed with ventilator-associated pneumonia (VAP);
Identified infection with MDR Klebsiella pneumoniae, Acinetobacter baumannii, or Pseudomonas aeruginosa via MROSE evaluation and antimicrobial susceptibility testing (AST) from this or other tertiary hospitals;
Aged 18 to 85 years;
Written informed consent obtained from the patient or legal guardian.
Disqualifiers
Pregnant or breastfeeding women;
FiO₂ ≥ 70% or PEEP ≥ 15 cmH₂O;
Hemodynamic instability (vasopressor dose increased by ≥30% in the last 6 hours or norepinephrine > 0.5 μg/kg/min);
Known allergy to phage components.
Trial design
Treatments tested in this trial
- Phage cocktail administered via nebulization
- Nebulized normal saline inhalation therapy
Treatment groups
248 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Chinese PLA General Hospital
Lead sponsor
Peking University Third Hospital
Collaborator
Zhengzhou Central Hospital
Collaborator
Henan Provincial People's Hospital
Collaborator
The First Affiliated Hospital of Zhengzhou University
Collaborator
Chinese the Eighth Medical Center of the General Hospital of the People's Liberation Army
Collaborator
The First Medical Center of Chinese PLA General Hospital
Collaborator
Source ClinicalTrials.gov